GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Inari Medical Inc (NAS:NARI) » Definitions » Total Liabilities

Inari Medical (Inari Medical) Total Liabilities : $209.3 Mil (As of Dec. 2023)


View and export this data going back to 2020. Start your Free Trial

What is Inari Medical Total Liabilities?

Inari Medical's Total Liabilities for the quarter that ended in Dec. 2023 was $209.3 Mil.

Inari Medical's quarterly Total Liabilities increased from Jun. 2023 ($89.32 Mil) to Sep. 2023 ($96.69 Mil) and increased from Sep. 2023 ($96.69 Mil) to Dec. 2023 ($209.33 Mil).

Inari Medical's annual Total Liabilities increased from Dec. 2021 ($72.33 Mil) to Dec. 2022 ($87.15 Mil) and increased from Dec. 2022 ($87.15 Mil) to Dec. 2023 ($209.33 Mil).


Inari Medical Total Liabilities Historical Data

The historical data trend for Inari Medical's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Inari Medical Total Liabilities Chart

Inari Medical Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Total Liabilities
Get a 7-Day Free Trial 83.69 13.84 72.33 87.15 209.33

Inari Medical Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Total Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 87.15 79.80 89.32 96.69 209.33

Inari Medical Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Inari Medical's Total Liabilities for the fiscal year that ended in Dec. 2023 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=76.339+(30.355+66.4
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit)
+36.231+0)
=209.3

Total Liabilities=Total Assets (A: Dec. 2023 )-Total Equity (A: Dec. 2023 )
=674.235-464.91
=209.3

Inari Medical's Total Liabilities for the quarter that ended in Dec. 2023 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=76.339+(30.355+66.4
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit)
+36.231+0)
=209.3

Total Liabilities=Total Assets (Q: Dec. 2023 )-Total Equity (Q: Dec. 2023 )
=674.235-464.91
=209.3

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Inari Medical Total Liabilities Related Terms

Thank you for viewing the detailed overview of Inari Medical's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.


Inari Medical (Inari Medical) Business Description

Traded in Other Exchanges
Address
6001 Oak Canyon, Suite 100, Irvine, CA, USA, 92618
Inari Medical Inc is a medical device company focused on developing products to treat patients suffering from Chronic Venous Disease. Its product portfolio includes ClotTriever, for the removal of the clot from peripheral blood vessels and treats patients suffering from deep vein thrombosis. The FlowTriever System product is used for the treatment of pulmonary embolism. The company generates revenue from the sale of ClotTriever and FlowTriever systems directly to hospitals located in the United States. Majority of revenue is generated from FlowTriever system.
Executives
William Hoffman director, officer: President and CEO C/O INARI MEDICAL, INC., 9 PARKER, SUITE 100, IRVINE CA 92618
Mitch C. Hill, officer: Chief Financial Officer 1009 TENNYSON DRIVE, SOUTHLAKE TX 76902
Andrew Hykes officer: Chief Operating Officer C/O INARI MEDICAL, INC., 9 PARKER AVENUE, SUITE 100, IRVINE CA 92618
Thomas Tu officer: Chief Medical Officer C/O INARI MEDICAL, INC., 9 PARKER AVENUE, SUITE 100, IRVINE CA 92618
Donald B Milder director ONE SANSOME STREET, SUITE 1650, SAN FRANCISCO CA 94104
Robert Keith Warner director C/O RXSIGHT, INC., 100 COLUMBIA, ALISO VIEJO CA 92656
Catherine M. Szyman director C/O EDWARDS LIFESCIENCES CORPORATION, ONE EDWARDS WAY, IRVINE CA 92614
Cynthia L Lucchese director 7966 N. ILLINOIS STREET, INDIANAPOLIS IN 46260
Mead Dana G Jr. director 2750 SAND HILL ROAD, MENLO PARK CA 94025
Rebecca Chambers director 3052 ORCHARD DR., SAN JOSE CA 95134
Jonathan D Root director 2735 SAND HILL ROAD, MENLO PARK CA 94025
Cooperatieve Gilde Healthcare Iv U.a. 10 percent owner NEWTONLANN 51, UTRECHT P7 3508AB
Kirk G. Nielsen director, 10 percent owner ONE SANSOME STREET, SUITE 3630, SAN FRANCISCO CA 94104
Gilde Healthcare Iv Management B.v. 10 percent owner NEWTONLAAN 91, UTRECHT P7 3584 BP
Gilde Healthcare Holding B.v. 10 percent owner NEWTONLAAN 91, PO BOX 85067, 3508 UTRECHT P7 AB